AR090126A1 - Composicion de doxilamina y piridoxina y/o sus metabolitos o sales - Google Patents
Composicion de doxilamina y piridoxina y/o sus metabolitos o salesInfo
- Publication number
- AR090126A1 AR090126A1 ARP130100543A ARP130100543A AR090126A1 AR 090126 A1 AR090126 A1 AR 090126A1 AR P130100543 A ARP130100543 A AR P130100543A AR P130100543 A ARP130100543 A AR P130100543A AR 090126 A1 AR090126 A1 AR 090126A1
- Authority
- AR
- Argentina
- Prior art keywords
- metabolites
- salt
- prodrugs
- derivatives
- iii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe un sistema de dosificación oral de liberación dual/forma de dosificación que comprende un componente/composición de liberación inmediata y un componente/composición de liberación retardada. Se describe también una composición de dosificación oral de liberación dual que comprende un componente de liberación inmediata y un componente de liberación retardada. Cada uno de los componentes/composiciones de liberación inmediata y componentes/composiciones de liberación retardada comprende uno o varios de doxilamina, uno de sus análogos, uno de sus derivados, uno de sus profármacos, uno de sus metabolitos y/o su sal y uno o varios de piridoxina, su sal, uno de sus metabolitos y/o una sal del metabolito. El sistema de dosificación oral de liberación dual/forma de dosificación exhibe un perfil farmacocinético mejorado respecto de la formulación corriente Diclectin® y es de utilidad, por ejemplo, para el alivio de los síntomas de náuseas y vómitos, por ejemplo, en el caso de náuseas y vómitos en el embarazo (NVP). Reivindicación 1: Una composición oral de liberación dual que comprende (a) uno o varios de (i) doxilamina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y (vi) una sal de cualquiera de (i) - (v); y (b) uno o varios de (i) piridoxina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y (vi) una sal de cualquiera de (i) - (v), donde dicha composición oral de liberación dual comprende: (A) un componente de liberación inmediata que comprende: (a) uno o varios de (i) doxilamina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y (vi) una sal de cualquiera de (i) - (v); y/o (b) uno o varios de (i) piridoxina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y (vi) una sal de cualquiera de (i) - (v); y (B) un componente de liberación retardada que comprende: (a) uno o varios de (i) doxilamina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y (vi) una sal de cualquiera de (i) - (v); y/o (b) uno o varios de (i) piridoxina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y (vi) una sal de cualquiera de (i) - (v); en donde dicho componente de liberación inmediata es para efectuar la liberación de (a) uno o varios de (i) doxilamina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y/o (vi) una sal de cualquiera de (i) - (v), y/o (b) (i) uno o varios de (i) piridoxina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y (vi) una sal de cualquiera de (i) - (v), que comienza antes de la liberación de (a) uno o varios de (i) doxilamina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y/o (vi) una sal de cualquiera de (i) - (v), y/o (b) (i) uno o varios de (i) piridoxina, (ii) uno de sus análogos, (iii) uno de sus derivados, (iv) uno de sus profármacos, (v) uno de sus metabolitos y (vi) una sal de cualquiera de (i) - (v), del componente de liberación retardada, dentro del tracto gastrointestinal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261601754P | 2012-02-22 | 2012-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090126A1 true AR090126A1 (es) | 2014-10-22 |
Family
ID=49004884
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100543A AR090126A1 (es) | 2012-02-22 | 2013-02-22 | Composicion de doxilamina y piridoxina y/o sus metabolitos o sales |
ARP210101574A AR122580A2 (es) | 2012-02-22 | 2021-06-09 | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101574A AR122580A2 (es) | 2012-02-22 | 2021-06-09 | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales |
Country Status (25)
Country | Link |
---|---|
US (3) | US9089489B2 (es) |
EP (2) | EP2787971A4 (es) |
JP (2) | JP5914701B2 (es) |
KR (1) | KR101588259B1 (es) |
CN (1) | CN104136004B (es) |
AR (2) | AR090126A1 (es) |
AU (1) | AU2013224598B2 (es) |
BR (1) | BR112014020186A8 (es) |
CA (1) | CA2848798C (es) |
CL (1) | CL2014001828A1 (es) |
CY (1) | CY1123122T1 (es) |
DK (1) | DK3326611T3 (es) |
ES (1) | ES2809713T3 (es) |
HK (1) | HK1197035A1 (es) |
HU (1) | HUE052301T2 (es) |
IL (1) | IL233644A (es) |
LT (1) | LT3326611T (es) |
MX (1) | MX355912B (es) |
NZ (1) | NZ627593A (es) |
PL (1) | PL3326611T3 (es) |
PT (1) | PT3326611T (es) |
SG (1) | SG11201403931YA (es) |
TW (1) | TWI638657B (es) |
UY (1) | UY34631A (es) |
WO (1) | WO2013123595A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE052301T2 (hu) | 2012-02-22 | 2021-04-28 | Duchesnay Inc | Doxil-amin és piridoxin és/vagy metabolitjainak vagy sóinak készítmény |
US10028941B2 (en) | 2013-07-22 | 2018-07-24 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
US9452181B2 (en) | 2013-07-22 | 2016-09-27 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
CN103432126A (zh) * | 2013-08-05 | 2013-12-11 | 北京阜康仁生物制药科技有限公司 | 一种治疗孕吐的药物组合物 |
PL3185856T3 (pl) * | 2014-08-29 | 2018-09-28 | Duchesnay Inc. | Wielomodalne formulacje uwalniania doksylaminy i pirydoksyny i/lub ich metabolitów lub soli |
US10500196B2 (en) | 2015-08-17 | 2019-12-10 | Alpha To Omega Pharmaceutical Consultants, Inc. | Transdermal and/or topical delivery systems composed of doxylamine succinate and pyridoxine hydrochloride in combination, or alone |
WO2019076966A1 (en) | 2017-10-17 | 2019-04-25 | Synthon B.V. | TABLETS COMPRISING TAMSULOSIN AND SOLIFENACIN |
ES2847648T3 (es) * | 2018-09-27 | 2021-08-03 | Inibsa Ginecologia S A | Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina |
AR121619A1 (es) * | 2020-03-25 | 2022-06-22 | Inibsa Ginecologia S A | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación |
WO2022254277A1 (en) * | 2021-05-31 | 2022-12-08 | Maneesh Pharmaceuticals Ltd | Extended release composition and its process for the preparation |
AU2021225255B1 (en) * | 2021-09-03 | 2022-06-16 | Patel, Mihir MR | Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting. |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
GB8524001D0 (en) | 1985-09-30 | 1985-11-06 | Glaxo Group Ltd | Pharmaceutical composition |
US4842867A (en) | 1986-05-09 | 1989-06-27 | Alza Corporation | Pulsed drug delivery of doxylamine |
IT1201136B (it) | 1987-01-13 | 1989-01-27 | Resa Farma | Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive |
US5110597A (en) | 1987-06-25 | 1992-05-05 | Alza Corporation | Multi-unit delivery system |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5387421A (en) | 1991-01-31 | 1995-02-07 | Tsrl, Inc. | Multi stage drug delivery system |
NZ242065A (en) | 1991-03-26 | 1996-06-25 | Csl Ltd | Delayed release implant having a degradable or rupturable polymeric coating |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
DE19716732C2 (de) | 1997-03-07 | 1999-03-25 | Max Delbrueck Centrum | Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US7744916B2 (en) | 1997-06-11 | 2010-06-29 | Umd, Inc. | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs |
FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
US6217904B1 (en) | 1999-04-06 | 2001-04-17 | Pharmaquest Ltd. | Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant |
US6197329B1 (en) | 1999-05-03 | 2001-03-06 | Drugtech Corporation | Anti-nausea compositions and methods |
US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
US6924273B2 (en) | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
CA2350195C (en) | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
DE60219607T2 (de) | 2001-01-09 | 2007-12-27 | Microchips, Inc., Bedford | Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation |
US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7704542B2 (en) | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
CA2392486A1 (en) | 2002-07-05 | 2002-12-08 | Duchesnay Inc. | Pharmaceutical dosage form bearing pregnancy-friendly indicia |
EP1528940B1 (en) | 2002-08-16 | 2011-04-13 | Microchips, Inc. | Controlled release device and method |
GB0229725D0 (en) | 2002-12-19 | 2003-01-29 | Univ Wales Medicine | Haplotype partitioning and growth hormone SNPs |
WO2006026768A1 (en) | 2004-09-01 | 2006-03-09 | Microchips, Inc. | Multi-cap reservoir devices for controlled release or exposure of reservoir contents |
GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
US20070141147A1 (en) * | 2005-12-21 | 2007-06-21 | Auriga Laboratories, Inc. | Sequential release pharmaceutical formulations |
JP5514547B2 (ja) | 2007-09-14 | 2014-06-04 | ロート製薬株式会社 | 眼科用組成物 |
KR101190708B1 (ko) * | 2010-03-12 | 2012-10-12 | 주식회사 대웅제약 | 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물 |
JP5905872B2 (ja) * | 2010-04-07 | 2016-04-20 | ルピン・リミテッド | タペンタドールの制御放出医薬組成物 |
JP2013533241A (ja) * | 2010-06-22 | 2013-08-22 | ティダブリューアイ・ファーマシューティカルズ・インコーポレイテッド | 食物効果が減少した制御放出組成物 |
WO2013123569A1 (en) | 2012-02-22 | 2013-08-29 | Duchesnay Inc. | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
HUE052301T2 (hu) | 2012-02-22 | 2021-04-28 | Duchesnay Inc | Doxil-amin és piridoxin és/vagy metabolitjainak vagy sóinak készítmény |
US9452181B2 (en) | 2013-07-22 | 2016-09-27 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
-
2013
- 2013-02-18 HU HUE17195445A patent/HUE052301T2/hu unknown
- 2013-02-18 CN CN201380009335.3A patent/CN104136004B/zh active Active
- 2013-02-18 NZ NZ627593A patent/NZ627593A/en unknown
- 2013-02-18 KR KR1020147025058A patent/KR101588259B1/ko active IP Right Grant
- 2013-02-18 CA CA2848798A patent/CA2848798C/en active Active
- 2013-02-18 SG SG11201403931YA patent/SG11201403931YA/en unknown
- 2013-02-18 MX MX2014008594A patent/MX355912B/es active IP Right Grant
- 2013-02-18 LT LTEP17195445.6T patent/LT3326611T/lt unknown
- 2013-02-18 PT PT171954456T patent/PT3326611T/pt unknown
- 2013-02-18 AU AU2013224598A patent/AU2013224598B2/en active Active
- 2013-02-18 ES ES17195445T patent/ES2809713T3/es active Active
- 2013-02-18 PL PL17195445T patent/PL3326611T3/pl unknown
- 2013-02-18 EP EP13751706.6A patent/EP2787971A4/en not_active Withdrawn
- 2013-02-18 EP EP17195445.6A patent/EP3326611B1/en active Active
- 2013-02-18 BR BR112014020186A patent/BR112014020186A8/pt not_active Application Discontinuation
- 2013-02-18 JP JP2014557951A patent/JP5914701B2/ja active Active
- 2013-02-18 DK DK17195445.6T patent/DK3326611T3/da active
- 2013-02-18 WO PCT/CA2013/050125 patent/WO2013123595A1/en active Application Filing
- 2013-02-21 TW TW102106004A patent/TWI638657B/zh active
- 2013-02-21 UY UY0001034631A patent/UY34631A/es active IP Right Grant
- 2013-02-22 AR ARP130100543A patent/AR090126A1/es not_active Application Discontinuation
-
2014
- 2014-03-27 US US14/228,228 patent/US9089489B2/en active Active
- 2014-07-10 CL CL2014001828A patent/CL2014001828A1/es unknown
- 2014-07-14 IL IL233644A patent/IL233644A/en active IP Right Grant
- 2014-10-23 HK HK14110576A patent/HK1197035A1/xx unknown
-
2015
- 2015-06-22 US US14/746,635 patent/US9375404B2/en active Active
-
2016
- 2016-01-13 JP JP2016004380A patent/JP2016053092A/ja active Pending
- 2016-05-24 US US15/163,621 patent/US9937132B2/en active Active
-
2020
- 2020-07-17 CY CY20201100652T patent/CY1123122T1/el unknown
-
2021
- 2021-06-09 AR ARP210101574A patent/AR122580A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090126A1 (es) | Composicion de doxilamina y piridoxina y/o sus metabolitos o sales | |
CR20150629A (es) | Compuestos químicos | |
CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
CL2012002318A1 (es) | Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer. | |
DK3287123T3 (da) | Vandig farmaceutisk formulering af tapentadol til oral administration | |
BR112014009146A2 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
NI201500096A (es) | Compuesto químicos | |
SMT201600341B (it) | Soluzione per somministrazione orale | |
CR20170077A (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
GT201300214A (es) | Moduladores de los receptores de hormonas nucleares | |
CR20130569A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo | |
CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
GT201500035A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
ECSP15050386A (es) | FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc | |
EA201591795A1 (ru) | Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120 | |
CR20130318A (es) | Nuevos compuestos de benzodioxol-piperazina | |
BRPI0909211B8 (pt) | formulação oral em forma de comprimido de compostos de tetraciclina | |
EA201990093A1 (ru) | Двухкомпонентная композиция | |
AR096725A1 (es) | Formulación de comprimidos masticables que comprende tadalafil o una de sus sales aceptables desde el punto de vista farmacéutico | |
BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
ES2604837T3 (es) | Formulación de liberación sostenida que contiene anticuerpos para administración ocular |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |